Daconib 45 mg contains Dacomitinib, an oral targeted anticancer medicine used to treat certain patients with advanced non-small cell lung cancer (NSCLC). It belongs to the tyrosine kinase inhibitor (TKI) class. This medicine works by blocking specific growth signals that help cancer cells multiply and survive.
Dacomitinib is particularly used for patients with metastatic NSCLC whose tumours have specific activating mutations in the epidermal growth factor receptor (EGFR) gene. Treatment requires appropriate molecular testing and specialist supervision.
Daconib 45 mg is a prescription medicine containing 45 mg of Dacomitinib. It is designed to target abnormal signalling pathways involved in cancer growth.
Dacomitinib is an irreversible pan-human epidermal growth factor receptor (HER) inhibitor. It targets EGFR (HER1), HER2, and HER4. By inhibiting these receptors, it helps reduce signals responsible for tumour cell growth and survival.
The 45 mg strength is the recommended starting dose for eligible adult patients under the approved treatment regimen. A treating oncologist may adjust the dose according to tolerability and adverse reactions.
Daconib 45 mg is indicated for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have specific EGFR mutations.
Its approved first-line use includes metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. A validated diagnostic test helps confirm whether a patient is suitable for treatment.
Dacomitinib may be prescribed when the cancer has spread beyond the original lung tissue and requires systemic treatment. It is not intended for every type of lung cancer. Its suitability depends on tumour characteristics, previous treatment, and the patient's overall clinical condition.
Dacomitinib works by blocking the activity of the HER family of receptor tyrosine kinases. These receptors normally transmit signals that regulate cell growth, division, and survival.
In certain lung cancers, EGFR mutations cause excessive activation of these signalling pathways. This can encourage cancer cells to grow and spread.
Dacomitinib binds irreversibly to EGFR, HER2, and HER4 receptors. This prevents the receptors from activating their downstream signalling pathways. Consequently, it helps slow cancer cell proliferation and may delay disease progression.
Unlike conventional chemotherapy, which affects many rapidly dividing cells, Dacomitinib is a targeted therapy designed to interfere with specific molecular pathways involved in tumour development.
The recommended adult dose of Daconib 45 mg is one tablet taken orally once daily, according to the prescribing information.
Important administration guidelines include:
Take the tablet at approximately the same time every day.
It can be taken with or without food.
Swallow the tablet whole with water.
Do not crush, chew, or break the tablet.
If a dose is missed, take the next dose at its regular time.
Do not take an additional tablet to replace a missed or vomited dose.
Treatment generally continues until cancer progression or unacceptable adverse reactions occur.
If side effects require treatment modification, an oncologist may reduce the daily dose from 45 mg to 30 mg and subsequently to 15 mg. Patients should never change their dosage without medical advice.
Daconib 45 mg may cause side effects because EGFR signalling also plays a role in normal skin and gastrointestinal function.
Common adverse reactions include:
Diarrhea
Skin rash and acne-like eruptions
Dry skin and itching
Inflammation around the fingernails or toenails
Mouth sores and stomatitis
Reduced appetite
Weight loss
Hair loss
Cough
Some reactions require immediate medical attention. Severe or persistent diarrhea can cause dehydration and electrolyte disturbances. Patients should contact their oncology team promptly if diarrhea develops.
Serious complications may include:
Interstitial lung disease (ILD): New or worsening cough, fever, or breathing difficulties require urgent assessment.
Severe skin reactions: Extensive rash, blistering, peeling, or painful skin changes require medical evaluation.
Dehydration: Persistent diarrhea or vomiting may cause significant fluid loss.
Embryo-fetal toxicity: Dacomitinib may cause harm to an unborn baby.
If ILD is confirmed, treatment must be permanently discontinued according to prescribing guidance.
Before starting Daconib 45 mg, patients should undergo appropriate EGFR mutation testing. The oncologist should review the patient's medical history, current medicines, and existing health conditions.
Important precautions include:
Lung health: Report new breathing difficulties, persistent cough, or fever immediately.
Skin care: Use gentle skincare products and protect the skin from excessive sunlight.
Hydration: Maintain adequate fluid intake, particularly during episodes of diarrhea.
Pregnancy: Dacomitinib can cause fetal harm. Effective contraception is recommended during treatment and for the recommended period after the final dose.
Breastfeeding: Breastfeeding is not recommended during treatment and for the specified period after the last dose.
Medication interactions: Inform the oncologist about prescription medicines, supplements, and acid-reducing treatments. Proton pump inhibitors may reduce Dacomitinib exposure.
Regular clinical assessments help evaluate treatment response and identify adverse reactions early.
Store Daconib 45 mg according to the manufacturer's instructions. Keep the tablets in their original packaging and protect them from moisture and excessive heat.
Keep this prescription medicine away from children and pets. Do not use tablets beyond their stated expiry date. Patients and caregivers should follow appropriate handling precautions when managing anticancer medicines.
What is Daconib 45 mg used for?
Daconib 45 mg is used for first-line treatment of metastatic NSCLC with specific EGFR mutations, including exon 19 deletions and exon 21 L858R substitutions.
How often should Daconib 45 mg be taken?
The recommended dose is 45 mg once daily. Treatment must follow the prescribing oncologist's instructions.
Does Dacomitinib require EGFR mutation testing?
Yes. Molecular testing is necessary to confirm the specific EGFR mutations associated with its approved indication.
Can Daconib 45 mg cause diarrhea?
Yes. Diarrhea is a common adverse reaction. Severe or persistent symptoms require prompt medical attention.
Can patients stop Daconib 45 mg when they feel better?
No. Patients should not discontinue treatment independently. The oncologist determines treatment duration based on disease progression and tolerability.
Daconib 45 mg (Dacomitinib) is an oral targeted therapy for adults with metastatic EGFR mutation-positive non-small cell lung cancer. It works by irreversibly inhibiting EGFR, HER2, and HER4 signalling pathways. Appropriate molecular testing, medical supervision, and regular monitoring are essential for safe treatment. Patients should use this medicine only with a valid prescription and guidance from a qualified oncologist.